

Special Issue

Epidemiology, Prognosis and Antimicrobial Treatment of Extensively Antibiotic-Resistant Bacterial Infections

Message from the Guest Editors

Infections caused by extensively drug-resistant (XDR) bacteria, including pandrug-resistant (PDR) bacteria, are increasingly being reported in several countries worldwide. These organisms are typically isolated from patients in intensive care units, but intra- and inter-hospital dissemination, and even international spread, may be substantial. Timely research on the population burden (prevalence and incidence), time trends, geographical spread, and dissemination in long-term care facilities and community settings of XDR and PDR bacteria is of crucial importance. Antimicrobial resistance phenotypes for which timely research is much needed include (but are not limited to):

- *Acinetobacter* spp susceptible only to one or more: polymyxins, tigecycline or minocycline or eravacycline, cefiderocol;
- Metallo-beta-lactamase producing *Pseudomonas aeruginosa* (i.e., co-resistant to carbapenems, ceftazidime/avibactam, ceftolozane/tazobactam, and imipenem/relebactam);
- Aztreonam/avibactam-resistant Enterobacterales;
- XDR *Stenotrophomonas maltophilia*;
- Cefiderocol-resistant XDR/PDR Gram-negative bacteria.

Guest Editors

Dr. Evangelos I. Kritsotakis

1. School of Medicine, University of Crete, Crete, Greece
2. School of Health and Related Research, University of Sheffield, Sheffield, UK

Dr. Stamatis Karakonstantis

Internal Medicine Department, Infectious Diseases Division, University Hospital of Heraklion, Heraklion, Greece

Deadline for manuscript submissions

closed (30 March 2022)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/71698

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)